Compare Stanley Black & Decker, Inc. (SWK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Viatris Inc — how do they compare? Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| SWK | VTRS | |
|---|---|---|
Market Cap | $14.17B | $19.09B |
52-Week High | $104.00 | $17.86 |
52-Week Low | $62.12 | $9.49 |
Enterprise Value | $18.33B | $31.21B |
Dividend Yield | 3.58% | 2.89% |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and management has raised 2026 EPS guidance to $4.60-$5.45. Recent portfolio optimization includes the sale of Excel Industries to Bad Boy Mowers, focusing on core brands. Valuation metrics appear reasonable with P/E of 22.94 and P/S of 0.93, while analyst consensus price target sits at $98.50 with 43% buy ratings.
SWK presents a mixed outlook with strong earnings momentum and cost transformation benefits offset by bearish technical indicators. The stock offers value potential with upside to analyst targets and dividend income, but faces execution risks in margin expansion and industrial demand volatility. Near-term support at $90 provides a key level to watch amid current market weakness.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
